Equiplex is an oil-based boldenone undecylenate injectable manufactured by Axiolabs and dosed at 200 or 300 mg/mL in a 10 mL vial.
Equiplex is an injectable anabolic-androgenic steroid containing boldenone undecylenate, a long-acting veterinary anabolic agent. Boldenone is structurally a 1-dehydro derivative of testosterone, differing by only one double bond at the 1-position. Its undecylenate ester provides an extended release profile, making it one of the longest-acting injectable anabolic steroids commonly referenced in non-medical bodybuilding contexts.
In veterinary medicine, boldenone undecylenate is approved for use in horses under the trade name Equipoise. It is recommended as an aid for treating debilitated horses when improvement in weight, haircoat, or general physical condition is desired, with a dosage of 0.5 mg per pound of body weight administered intramuscularly and repeated at three-week intervals. In non-medical bodybuilding settings, boldenone undecylenate is commonly referenced for lean mass gains, increased vascularity, and enhanced endurance, though such use falls outside approved indications and the compound is not approved for human use in most countries.
Boldenone acts as an androgen by binding to the androgen receptor, which regulates gene transcription and stimulates anabolic processes. It has been characterized as having distinct anabolic properties with a certain degree of androgenic activity, and it does not have marked antigonadotropic properties or produce clear-cut effects on the endometrium. Boldenone increases nitrogen retention and protein synthesis, stimulates appetite, and promotes the release of erythropoietin in the kidneys. Non-medical use at supraphysiologic doses carries significant risks, particularly elevated hematocrit and red blood cell count.
Equiplex uses MCT oil as its carrier oil, providing the oil base for the boldenone undecylenate formulation.
Boldenone undecylenate is a long-acting veterinary anabolic steroid with a distinctive profile, characterized by its extended release and reputation for appetite stimulation and endurance enhancement.
Boldenone undecylenate is the undecylenic acid ester of boldenone (17β-hydroxy-androsta-1,4-dien-3-one). The esterification at the 17-beta hydroxyl group slows the release of boldenone from the injection site, producing a prolonged duration of activity. Boldenone is a steroid hormone with androgenic activity that binds to the androgen receptor, regulating gene transcription.
Boldenone was synthesized in an attempt to create a long-acting injectable methandrostenolone for androgen deficiency disorders, and it acts similar to methandrostenolone with fewer adverse androgenic effects. Although commonly compared to nandrolone, boldenone lacks progesterone receptor interaction and the associated progestogenic side effects. Boldenone is not a 19-nortestosterone derivative; it is a 1-dehydro derivative of testosterone.
The biological half-life of boldenone is approximately 14 days. In veterinary medicine, the dosage for horses is 0.5 mg per pound of body weight administered intramuscularly, with treatment repeated at three-week intervals. The long half-life and slow onset mean that blood levels accumulate gradually, with many non-medical users reporting that noticeable effects do not manifest until weeks 4–6 of a cycle.
Boldenone undecylenate's long half-life of approximately 14 days supports less frequent administration, while its reputation for appetite stimulation distinguishes it from many other anabolic steroids in non-medical discussions.
Axiolabs produces several injectable anabolic products referenced in different contexts. Equiplex is a boldenone undecylenate product, placing it among the long-acting injectable options alongside Decaplex 250 (nandrolone decanoate) and Testaplex C 250 (testosterone cypionate).
For bodybuilders considering shorter-acting alternatives, Duraplex 100 (nandrolone phenylpropionate) offers a faster-release option. For cutting phases, Mastaplex 100 (drostanolone propionate) is commonly discussed. The choice between these compounds depends on individual goals, cycle duration, and tolerance for hematocrit elevation, which is particularly pronounced with boldenone.
The information below is provided for educational reference only. Boldenone undecylenate is a veterinary prescription medication; it is not approved for human use in most countries. Non-medical use falls outside approved indications and carries significant health risks.
In veterinary practice, the dosage for horses is 0.5 mg per pound (approximately 1.1 mg/kg) administered intramuscularly, repeated at three-week intervals. In non-medical bodybuilding contexts, boldenone undecylenate is commonly referenced in the range of 200–400 mg per week for beginner-to-intermediate users, with more experienced users sometimes referencing 400–600 mg per week. Doses above 800 mg per week are associated with increased hematocrit and cardiovascular risks.
| Use Case | Common Reference Range | Injection Frequency |
|---|---|---|
| Veterinary (horses, approved) | 0.5 mg / lb body weight | Every 3 weeks |
| Bodybuilding (non-medical, beginner) | 200–400 mg / week | Once or twice weekly |
| Bodybuilding (non-medical, advanced) | 400–600 mg / week | Split twice weekly |
In non-medical bodybuilding contexts, boldenone undecylenate is frequently referenced as part of longer cycles, typically 12–20 weeks, due to its slow onset. It is often stacked with a testosterone base, as boldenone is suppressive to the hypothalamic-pituitary-gonadal axis. Some users report that boldenone can lower estrogen levels when stacked with testosterone, requiring adjustment of the testosterone dose. It may also be combined with oral compounds such as Methanoplex during the initial weeks of a mass-building protocol.
The most clinically significant side effect of boldenone undecylenate is increased hematocrit and red blood cell count, which is more pronounced than with most other anabolic steroids. Hematocrit monitoring is described as non-negotiable, with blood donation often recommended if hematocrit exceeds 52%. Increased appetite is a reliable effect that can be a benefit or hindrance depending on goals.
Anxiety and restlessness are widely reported anecdotally, particularly at higher doses. Lipid profile changes, including decreased HDL cholesterol, have been observed in animal studies. Boldenone is also profoundly suppressive to endogenous testosterone production.
Boldenone undecylenate is suppressive to the hypothalamic-pituitary-gonadal axis, and post-cycle therapy is commonly recommended after a cycle. Due to the long undecylenate ester, PCT should not begin until 4–5 weeks after the final injection to allow for ester clearance. Agents such as Clomiplex and Tamoxiplex are frequently referenced for this purpose.
Dosing strategies and support protocols should account for individual experience and health status. The information above is for educational reference and does not constitute medical advice.
Boldenone undecylenate is a veterinary anabolic steroid not approved for human use. It carries significant risks including hematocrit elevation and reproductive toxicity. Medical evaluation is required before any consideration of use.
Boldenone undecylenate is approved only for veterinary use in horses and is not approved for human use in most countries. The FDA-approved labeling for Equipoise explicitly states: "For horses only. Do not use in horses intended for human consumption". Non-medical use in humans falls outside approved indications and is illegal in many jurisdictions.
Boldenone is classified under GHS hazard statements as suspected of causing cancer (H351), may damage fertility or the unborn child (H360), and may cause harm to breast-fed children (H362). The European Chemicals Agency classification includes Reproductive Toxicity Category 1A and Carcinogenicity Category 2.
Boldenone undecylenate is not approved for bodybuilding or athletic performance enhancement in humans. Non-medical use falls outside approved indications and may carry additional health risks beyond those associated with supervised veterinary use.
Increased hematocrit and red blood cell count is the primary and most clinically significant side effect of boldenone undecylenate, more pronounced than with most other anabolic steroids. Elevated hematocrit increases blood viscosity and cardiovascular risk, with symptoms including persistent headaches, dizziness, blurred vision, and chest pain.
Animal studies have demonstrated significant harmful effects on reproductive functions. In male rabbits, boldenone undecylenate caused significant reductions in serum testosterone levels, seminal volume, sperm motility, and sperm count, with marked histopathological alterations in the testes and epididymis. A separate study reported reduction in testicular and epididymal mass, implying potential testicular atrophy, and concluded that the drug causes infertility in the long run.
Other reported effects include increased appetite, anxiety and restlessness, mild acne and oily skin, suppression of endogenous testosterone production, and elevated blood pressure secondary to increased blood volume. Lipid profile changes, including decreased HDL cholesterol, have been observed in animal studies.
Boldenone undecylenate is contraindicated in horses intended for human consumption and in stallions, pregnant mares, and brood mares during the breeding season due to absence of safety data. In humans, any consideration of use requires medical evaluation including assessment of hematocrit, lipid profile, and reproductive function. Polycythemia or elevated baseline hematocrit (above 50%) is a contraindication.
In non-medical contexts, hematocrit monitoring is described as non-negotiable, with baseline, week 6, and week 12 complete blood count testing recommended. Blood donation is often recommended if hematocrit exceeds 52%. These monitoring practices are not a substitute for clinical oversight, which is required for safe use of any anabolic steroid.
Store at room temperature; avoid freezing. Keep away from heat, sparks, and flames. Store in properly labeled containers. Keep out of reach of children. Do not use if the product appears damaged or compromised.
Equiplex is shipped in original manufacturer packaging with discreet, privacy-focused handling.
Outer packaging remains discreet with no external product details. Products are supplied in original manufacturer presentation.
To verify product authenticity, examine the packaging for manufacturer security features and compare against official Axiolabs presentation. Original packaging and consistent labeling help confirm product legitimacy.
For complete delivery details, please see our Shipping Info page.
Proper storage conditions help preserve formulation stability and overall product integrity throughout shelf life.
Store at room temperature; avoid freezing. Keep away from heat, sparks, and flames. Store in properly labeled containers. Keep the vial in its original packaging until use. Do not use if the product appears compromised or if the solution appears cloudy, discolored, or contains particulate matter.
Keep out of reach of children. Follow proper handling and sterile injection practices when administering the product.
Answers to common questions about Equiplex, boldenone undecylenate, dosing, and product characteristics.
Equiplex contains boldenone undecylenate, a veterinary anabolic steroid. In veterinary medicine, it is approved for treating debilitated horses when improvement in weight, haircoat, or general physical condition is desired. In non-medical bodybuilding contexts, it is commonly referenced for lean mass gains and vascularity, though such use falls outside approved indications and the compound is not approved for human use in most countries.
In veterinary practice, boldenone undecylenate is administered every three weeks. In non-medical bodybuilding contexts, it is typically referenced as being administered once or twice weekly due to the long undecylenate ester. The biological half-life is approximately 14 days.
Yes. Boldenone undecylenate suppresses the hypothalamic-pituitary-gonadal axis, and post-cycle therapy is commonly recommended after a cycle. Due to the long ester, PCT should not begin until 4–5 weeks after the final injection to allow for ester clearance. Agents such as Clomiplex or Tamoxiplex are commonly referenced for this purpose.
Boldenone binds to the androgen receptor and regulates gene transcription, stimulating anabolic processes. It increases nitrogen retention, protein synthesis, appetite, and stimulates the release of erythropoietin in the kidneys. In veterinary medicine, it has marked anabolic effects in debilitated horses, improving appetite, vigor, musculature, and haircoat.
Due to the very long undecylenate ester, blood levels accumulate gradually. In non-medical discussions, minimal noticeable effects are reported during weeks 1–3, with blood levels approaching steady state by weeks 4–6. Visible changes in body composition typically begin to manifest by weeks 8–12.
There is no universally "best" injectable for lean gains. Boldenone undecylenate is commonly referenced for this purpose, but Testaplex P 100 and Mastaplex 100 are also widely discussed. The appropriate choice depends on individual goals, cycle duration, and tolerance for hematocrit elevation, which is particularly pronounced with boldenone.
Both are long-acting injectable anabolic steroids, but they have different profiles. Boldenone is a 1-dehydro derivative of testosterone and lacks progesterone receptor interaction. Nandrolone decanoate is a 19-nor compound and is commonly referenced for joint support. Axiolabs offers Decaplex 250 as its nandrolone decanoate product.
Boldenone is structurally a 1-dehydro derivative of testosterone, differing by one double bond at the 1-position. It has lower androgenic activity than testosterone and does not aromatize to estrogen to the same extent. Testosterone is commonly used as a base compound alongside boldenone in non-medical cycles.
In non-medical bodybuilding contexts, 400 mg per week is within the commonly referenced range of 200–400 mg per week for beginner-to-intermediate users. Equiplex is available at 200 or 300 mg/mL, so 400 mg would equal 2 mL or 1.33 mL per week respectively. Dosage appropriateness depends on individual factors and the overall cycle context.
Equiplex is available at 200 mg/mL or 300 mg/mL of boldenone undecylenate. It is supplied in a 10 mL vial, giving 2,000 mg or 3,000 mg of total labeled boldenone undecylenate content per vial.
Lab testing information for Equiplex is not available on this page. For product-specific testing inquiries, please contact customer support.
Yes. Increased appetite is widely reported as a reliable effect of boldenone undecylenate, and it is described as significant and dose-dependent. In veterinary medicine, appetite improvement is one of the noted clinical effects in debilitated horses. This effect can be a benefit or hindrance depending on the user's goals.